Bazedoxifene

Chemical formula: C₃₀H₃₄N₂O₃  Molecular mass: 470.613 g/mol  PubChem compound: 154257

Interactions

Bazedoxifene interacts in the following cases:

Hepatic impairment

Safety and efficacy of bazedoxifene have not been evaluated in patients with hepatic impairment; use in this population is not recommended.

Patients with hepatic impairment showed a 4.3-fold increase in area under the curve (AUC) [on average] compared with controls.

Severe renal impairment

Bazedoxifene has not been sufficiently evaluated in patients with severe renal impairment; caution should be used in this population.

Substances known to induce uridine diphosphate glucuronosyltransferase (UGT)

Bazedoxifene undergoes metabolism by uridine diphosphate glucuronosyltransferase (UGT) enzymes in the intestinal tract and liver. The metabolism of bazedoxifene may be increased by concomitant use of substances known to induce UGTs, such as rifampicin, phenobarbital, carbamazepine, and phenytoin, potentially leading to decreased systemic concentrations of bazedoxifene.

Breast cancer

The safety of bazedoxifene in patients with breast cancer has not been studied. No data are available on the concomitant use with agents used in the treatment of early or advanced breast cancer. Therefore, bazedoxifene is not recommended for treatment or prevention of breast cancer.

Hypertriglyceridaemia

Bazedoxifene has not been studied in women with triglyceride levels >300 mg/dl (>3.4 mmol/litre). It may increase serum triglyceride levels; therefore, caution should be exercised in patients with known hypertriglyceridaemia.

Hormone-binding globulin

In a 30-day study, bazedoxifene increased hormone-binding globulin concentrations, including corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG) and thyroxine-binding globulin (TBG).

Pregnancy

Bazedoxifene is only for use in postmenopausal women. It is contraindicated in women of child-bearing potential. There are no data from the use of bazedoxifene in pregnant women. Studies in rabbits have shown reproductive toxicity. The potential risk for humans is unknown

Nursing mothers

It is not known whether bazedoxifene is excreted in human milk. Bazedoxifene is only indicated for use in postmenopausal women and should not be used during breast-feeding.

Effects on ability to drive and use machines

Bazedoxifene has minor influence on the ability to drive and use machines.

In clinical trials, somnolence was reported as an adverse reaction, and patients should be advised on the potential effect on driving and using machines.

Patients may experience visual symptoms such as visual acuity disturbance or blurred vision. If such symptoms occur, patients should avoid driving or use of machines that requires accurate visual perception until symptoms have resolved, or until they have received medical advice that it is safe to do so.

Adverse reactions


Summary of the safety profile

The safety of bazedoxifene has been evaluated in two multicentre, double-blind, randomised, placebo-and active-control, Phase 3 trials: 7,492 evaluable postmenopausal women in a three-year osteoporosis treatment trial (1,886 women received bazedoxifene 20 mg; 1,872 women received bazedoxifene 40 mg; 1,849 women received raloxifene; 1,885 women received placebo) and 1,583 evaluable postmenopausal women in a 2-year osteoporosis prevention trial (321 women received bazedoxifene 10 mg; 322 women received bazedoxifene 20 mg; 319 women received bazedoxifene 40 mg; 311 women received raloxifene; 310 women received placebo).

The majority of adverse reactions occurring during the clinical trials were mild to moderate in severity and did not lead to discontinuation of therapy. The most frequent drug-related adverse reactions in double-blind, randomised studies were hot flushes and muscle spasms (includes leg cramps).

System organ
class
Very
common
Common Uncommon Frequency not
known (cannot
be estimated
from available
data)
Immune system
disorders
 Hypersensitivity  
Nervous system
disorders
 Somnolence  
Eye disorders   Retinal vein
thrombosis*
Vision
disorders/Ocular
events#
Cardiac disorders    Palpitations
Vascular
disorders
Hot flush Deep vein
thrombosis*,
thrombophlebitis
superficial
 
Respiratory,
thoracic and
mediastinal
disorders
  Pulmonary
embolism*
 
Gastrointestinal
disorders
 Dry mouth   
Skin and
subcutaneous
tissue disorders
 Urticaria, rash,
pruritus
  
Musculoskeletal
and connective
tissue disorders
Muscle
spasms
(includes
leg cramps)
   
General disorders
and administration
site conditions
Oedema
peripheral
   
Investigations  Blood
triglycerides
increased, alanine
aminotransferase
increased,
aspartate
aminotransferase
increased.
  

Tabulated list of adverse reactions

The safety data in the following table are derived from both clinical trials and spontaneous post-marketing reporting.

Adverse reactions are categorized according to the following frequencies: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Description of selected adverse reactions

* In the osteoporosis treatment trial in 7,492 evaluable subjects (mean age=66 years), the bazedoxifene-treated women had an increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism and retinal vein thrombosis). The rate per 1,000 women-years through the 3-year study period was 2.86 in the bazedoxifene 20 mg group and 1.76 in the placebo group, and through the 5-year study period was 2.34 in the bazedoxifene 20 mg group and 1.56 in the placebo group. The rate per 1,000 women-years through the 7 year study period was 2.06 in the bazedoxifene 20 mg group and 1.36 in the placebo group. The rate of VTE was highest in the first year with a relative risk of 2.69. After 3 years the relative risk was 1.63 and after a 5 year study period the relative risk was 1.50. After 7 year study period the relative risk was 1.51. Other venous thromboembolic events could also occur.

# There have been post-marketing reports of ocular events other than retinal vein thrombosis. These reports include visual acuity reduced, blurred vision, photopsia, visual field defect, visual impairment, dry eye, eyelid oedema, blepharospasm, eye pain and eye swelling. The underlying nature of these events is uncertain. If ocular symptoms occur, patients should be advised to seek medical attention.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.